Yahoo · Oct 25, 2026
ESMO26: Clinical progress shifts a historically difficult pancreatic cancer landscape
Revolution Medicines’ impressive daraxonrasib data has spurred hope in the pancreatic cancer space.
RV
NASDAQ · RVMD
Revolution Medicines, Inc.
Healthcare · Biotechnology
$177.65
Down-$22.05 (-11.04%)
Updated Nov 6, 2026, 10:34 AM
SID Score
6.7/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 15.18B
- P/E ratio
- -15.46
- Dividend yield
- 0.00%
- 52-week range
- $61.50 – $224.31
- Volume
- 7.82M
- Avg. volume
- 2.27M
Price performance · RVMD
RVMD price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 5, 2026
RVMD closed at $177.65 after 21 trading sessions, down 5.57% for the selected period.
- Last close
- $177.65
- Period change
- -5.57%
- Period low
- $177.65
- Period high
- $199.70
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 5, 2026 | $209.05 | $211.41 | $177.08 | $177.65 | 7.82M |
| Nov 4, 2026 | $198.50 | $201.79 | $192.34 | $199.70 | 2.55M |
| Nov 3, 2026 | $188.63 | $197.00 | $188.63 | $194.23 | 1.44M |
| Nov 2, 2026 | $190.71 | $192.98 | $187.12 | $188.17 | 1.37M |
| Oct 30, 2026 | $188.38 | $192.75 | $187.2775 | $191.31 | 1.1M |
| Oct 29, 2026 | $187.38 | $192.00 | $187.37 | $190.27 | 1.32M |
| Oct 28, 2026 | $185.08 | $188.85 | $183.855 | $188.72 | 890.43K |
| Oct 27, 2026 | $182.68 | $187.655 | $181.20 | $186.22 | 1.17M |
| Oct 26, 2026 | $186.99 | $188.30 | $181.00 | $183.90 | 1.66M |
| Oct 23, 2026 | $187.59 | $189.52 | $183.61 | $186.99 | 1.72M |
| Oct 22, 2026 | $192.06 | $194.59 | $185.34 | $187.69 | 1.49M |
| Oct 21, 2026 | $198.71 | $203.49 | $193.97 | $194.28 | 1.88M |
| Oct 20, 2026 | $181.50 | $197.14 | $180.00 | $196.55 | 2.74M |
| Oct 19, 2026 | $179.98 | $183.87 | $177.00 | $182.15 | 1.98M |
| Oct 16, 2026 | $188.86 | $189.68 | $175.91 | $177.96 | 2.97M |
| Oct 15, 2026 | $193.31 | $195.94 | $189.14 | $189.26 | 1.57M |
| Oct 14, 2026 | $186.84 | $197.00 | $185.8801 | $193.52 | 2.46M |
| Oct 13, 2026 | $191.57 | $193.61 | $187.14 | $188.44 | 2.94M |
| Oct 12, 2026 | $187.79 | $194.26 | $184.76 | $193.95 | 1.67M |
| Oct 9, 2026 | $186.01 | $193.50 | $184.3701 | $189.76 | 2.21M |
| Oct 8, 2026 | $198.51 | $199.64 | $180.49 | $188.12 | 4.86M |
Latest RVMD news
The latest Smart Investors Daily articles mentioning RVMD.
Stock researchCompany · Overview
Company
Market Activity
Research & News
RVMD research
Overview
Company profile and research snapshot.
Company profile
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $82.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 5, 2026 | TD Cowen | Buy | — |
| Nov 5, 2026 | Guggenheim | Buy | — |
| Nov 5, 2026 | Truist Securities | Buy | — |
| Nov 5, 2026 | Piper Sandler | Overweight | — |
| Nov 5, 2026 | RBC Capital | Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 24, 2026
Revolution Medicines (RVMD) Stock Looks Above Fair Value Today
Revolution Medicines has become one of the most eye-catching moves in biotech over the past few years, and the latest regulatory milestones now put a sharper spotlight on what investors are actually paying for on its balance sheet. With the share price far above where it traded three years ago, the key issue is whether that price can be squared with the company’s book value today. Over the past 3 years the stock has returned roughly 9x for shareholders, which puts pressure on the current...
Yahoo · Oct 24, 2026
Revolution Medicines (RVMD) Following New Pancreatic Cancer Data Looks Undervalued
Revolution Medicines (RVMD) is back in focus after presenting new subgroup data from its Phase 3 RASolute 302 trial at the ESMO 2026 Congress in Madrid, highlighting overall survival outcomes with RASONQUE in metastatic pancreatic cancer. Against that clinical backdrop, Revolution Medicines’ share price has been volatile in the short term but strong over longer periods, with a 7 day share price return of 5.07% and a year to date share price return of 136.64%. This is alongside a 1 year total...
Yahoo · Oct 23, 2026
Moderna’s Cancer-Vaccine Leak Spurred Panic Selling as Wall Street Wanted a Cure
Moderna and Merck’s cancer vaccine reduced the risk of melanoma recurrence or death by 42%, but investors questioned its potential across other cancers.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
